La cadena de opciones muestra datos clave de las opciones de acciones de Pear Therapeutics Inc Class A a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Pear Therapeutics Inc Class A..

Pear Therapeutics Inc Class A (OTC:PEARQ) Bolsa, Cadena de Opciones

Pear Therapeutics Inc Class A

<p>BancFirst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANF#NASDAQ">BANF</a>) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.62 by 3.7 percent. This is a 15.07 percent increase over earnings of $1.46 per share from the same period last year.</p>


Earnings

Earnings Beats

News

BANF

BancFirst Q4 2024 GAAP EPS $1.68 Beats $1.62 Estimate

<p><strong>Preliminary Estimated Financial Results for the Quarter and Full Year ended December&nbsp;31, 2024</strong></p>
<p>Twilio expects to report:</p>
<p>&nbsp;</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>•</td>
<td>&nbsp;</td>
<td>Revenue growth for the fourth quarter of 2024 of approximately 11% year-over-year.</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p>&nbsp;</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>•</td>
<td>&nbsp;</td>
<td>Positive GAAP income from operations for the fourth quarter of 2024.</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p>&nbsp;</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>•</td>
<td>&nbsp;</td>
<td>Non-GAAP income from operations for the fourth quarter of 2024 and fiscal year 2024 above the top-end of the guidance ranges it originally provided on October&nbsp;30, 2024.</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p>&nbsp;</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>•</td>
<td>&nbsp;</td>
<td>Free cash flow for fiscal year 2024 within the range it originally provided on October&nbsp;30, 2024.</td>
</tr>
</tbody>
</table>
<p></p></figure></p>


Guidance

TWLO

Twilio Announces 11% Revenue Growth For Q4 2024, Reports Positive GAAP Income; Non-GAAP Income Exceeds Guidance; Fiscal Year 2024 Free Cash Flow Meets Expectations

<p>MidWestOne Financial Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOFG#NASDAQ">MOFG</a>) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.72 by 8.33 percent.</p>


MOFG

MidWestOne Financial Gr Q4 2024 Adj EPS $0.78 Beats $0.72 Estimate

<p>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) reported quarterly losses of $(0.08) per share.  The company reported $19.70 million in sales this quarter.</p>


Zeo Energy Q3 EPS $(0.08), Sales $19.70M

GRND

Grindr Reports Redemption Of Public Warrants And Private Placement Warrants

WIIM

EWBC

East West Bancorp shares are trading lower after the company reported worse-than-expected Q4 EPS results.

<p>The earnings results for <strong>CSX</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) for Q4 were made public on Thursday, January 23, 2025 at 04:01 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>CSX missed estimated earnings by 0.0%, reporting an EPS of $0.42 versus an estimate of $0.42.</p>
<p>Revenue was down $140.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company missed on EPS by $0.02, resulting in a 7.000000000000001% drop change in the share price the following day.</p>
<p>Here's a look at CSX's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.48</td>
<td>0.48</td>
<td>0.45</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.46</td>
<td>0.49</td>
<td>0.46</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>3.67B</td>
<td>3.70B</td>
<td>3.66B</td>
<td>3.63B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.62B</td>
<td>3.70B</td>
<td>3.68B</td>
<td>3.68B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for CSX <a href="https://www.benzinga.com/quote/CSX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: CSX Q4 Earnings

<p>The Q4 earnings report for <strong>Intuitive Surgical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) was released on Thursday, January 23, 2025 at 04:04 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Intuitive Surgical beat estimated earnings by 23.0%, reporting an EPS of $2.21 versus an estimate of $1.79.</p>
<p>Revenue was up $485.70 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company beat on EPS by $0.21 in the previous quarter, leading to a 10.0% increase share price change the next day.</p>
<p>Here's a look at Intuitive Surgical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.63</td>
<td>1.54</td>
<td>1.41</td>
<td>1.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.84</td>
<td>1.78</td>
<td>1.50</td>
<td>1.60</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.00B</td>
<td>1.97B</td>
<td>1.87B</td>
<td>1.87B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.04B</td>
<td>2.01B</td>
<td>1.89B</td>
<td>1.93B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Intuitive Surgical <a href="https://www.benzinga.com/quote/ISRG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ISRG

Intuitive Surgical Earnings Report: Q4 Overview

<p><strong>OceanFirst Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCFC#NASDAQ">OCFC</a>) released its Q4 earnings on Thursday, January 23, 2025 at 04:15 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>OceanFirst Financial beat estimated earnings by 3.0%, reporting an EPS of $0.38 versus an estimate of $0.37.</p>
<p>Revenue was down $4.50 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 2.0% drop share price change the next day.</p>
<p>Here's a look at OceanFirst Financial's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.38</td>
<td>0.43</td>
<td>0.41</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.39</td>
<td>0.39</td>
<td>0.44</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>83.18M</td>
<td>85.46M</td>
<td>87.40M</td>
<td>90.36M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>82.22M</td>
<td>82.26M</td>
<td>86.22M</td>
<td>87.82M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for OceanFirst Financial <a href="https://www.benzinga.com/quote/OCFC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OCFC

OceanFirst Financial Q4 Earnings Assessment

<p><strong>Byline Bancorp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BY#NYSE">BY</a>) just disclosed its Q4 earnings on Thursday, January 23, 2025 at 04:15 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Byline Bancorp beat estimated earnings by 13.0%, reporting an EPS of $0.69 versus an estimate of $0.61.</p>
<p>Revenue was up $3.88 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.05 in the last quarter, resulting in a 1.0% increase share price change the following day.</p>
<p>Here's a look at Byline Bancorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.65</td>
<td>0.63</td>
<td>0.63</td>
<td>0.67</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.70</td>
<td>0.68</td>
<td>0.70</td>
<td>0.73</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>101.08M</td>
<td>99.23M</td>
<td>98.06M</td>
<td>101.40M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>101.84M</td>
<td>99.37M</td>
<td>101.01M</td>
<td>100.79M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Byline Bancorp <a href="https://www.benzinga.com/quote/BY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Byline Bancorp: Q4 Earnings Insights

<p><strong>SB Finl Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFG#NASDAQ">SBFG</a>) just disclosed its Q4 earnings on Thursday, January 23, 2025 at 04:15 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>SB Finl Gr beat estimated earnings by 27.0%, reporting an EPS of $0.52 versus an estimate of $0.41.</p>
<p>Revenue was up $339 thousand from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company missed on EPS by $0.01 in the previous quarter, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at SB Finl Gr's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.42</td>
<td>0.35</td>
<td>0.30</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.41</td>
<td>0.46</td>
<td>0.33</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>9.70M</td>
<td>9.40M</td>
<td>9.50M</td>
<td>9.40M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>14.31M</td>
<td>14.04M</td>
<td>13.13M</td>
<td>15.12M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for SB Finl Gr <a href="https://www.benzinga.com/quote/SBFG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SBFG

Earnings Breakdown: SB Finl Gr Q4

<p><strong>Eastern Bankshares</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBC#NASDAQ">EBC</a>) reported its Q4 earnings results on Thursday, January 23, 2025 at 04:17 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Eastern Bankshares beat estimated earnings by 17.0%, reporting an EPS of $0.34 versus an estimate of $0.29.</p>
<p>Revenue was up $56.50 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company missed on EPS by $0.08 in the previous quarter, leading to a 5.0% drop share price change the next day.</p>
<p>Here's a look at Eastern Bankshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.33</td>
<td>0.21</td>
<td>0.20</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.25</td>
<td>0.22</td>
<td>0.23</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>182.28M</td>
<td>133.13M</td>
<td>134.92M</td>
<td>129.71M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>203.38M</td>
<td>154.00M</td>
<td>157.59M</td>
<td>160.05M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Eastern Bankshares <a href="https://www.benzinga.com/quote/EBC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Eastern Bankshares Q4 Earnings

3D Systems And Daimler Buses Announce Solution For Remote Spare Part Printing

<p>Grindr announced today that it expects full year 2024 revenue growth to exceed the Company's previously provided outlook of at least 29% revenue growth year-over-year.&nbsp;</p>
<p>Grindr also announced today that it reaffirms its previously provided outlook for Adjusted EBITDA margin of 42% or greater for full year 2024.</p>
<p>The increase in revenue growth versus the financial outlook was driven by a combination of outperformance in Grindr's direct ad sales business, which significantly exceeded expectations in December 2024, and continued strength on the direct revenue side (subscriptions and add ons). Financial results for the fourth quarter and full year 2024 are expected to be reported in March 2025.</p>


Grindr Now Expects 2024 Revenue Of $343M - $345M (Est $337.24M), Representing Revenue Growth Of 32%-33% YoY (Prior View At Least 29% Revenue Growth)

<ul>
<li><i>Adolescents receive a weight-based dose equivalent to the 50 mg adult dose</i></li>
<li><i>Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in the ongoing open label extension (OLE) study</i></li>
<li><i>Larimar is continuing to enroll adolescent patients and plans to initiate a cohort of children 2-11 years old in 1H 2025</i></li>
<li><i>Long-term 50 mg data from adults in OLE study and&nbsp;available adolescent PK run-in data expected mid-2025</i><br /><br />&nbsp;</li>
</ul>
<p>BALA CYNWYD, Pa., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that dosing of adolescents 12-17 years old has started in the Company's pediatric PK run-in study for patients with Friedreich's ataxia (FA).</p>


Biotech

General

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Announces Dosing Of Adolescents In PK Run-In Study For Friedreich's Ataxia; Plans Cohort For Ages 2-11 In H1 2025; Long-Term Data Expected Mid-2025

<p>The Sackler family and <strong>Purdue Pharma</strong> have agreed to pay $7.4 billion to resolve nationwide opioid litigation, marking a major milestone in efforts to hold the makers of the addictive pain medication <a href="https://www.benzinga.com/markets/cannabis/21/07/21902857/15-states-settle-with-opioid-maker-purdue-pharma-for-4-5b-the-most-that-individuals-have-ever-pa">OxyContin</a> accountable for their role in the opioid crisis. This increased settlement, announced Thursday, follows the U.S. Supreme Court's <a href="https://www.benzinga.com/news/large-cap/24/06/39531087/purdue-pharma-bankruptcy-plan-rejected-by-supreme-court-billionaire-sacklers-to-face-lawsuits">June 2024 rejection</a> of a prior deal and, if approved, will conclude the most expensive corporate bankruptcy tied to the <a href="https://www.benzinga.com/topic/opioid-crisis">opioid epidemic</a>, which has claimed at least <a href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm" target="_blank" rel="noreferrer noopener">106,000 lives</a> in the U.S.</p>
<p><strong>What Happened</strong>: Purdue Pharma developed and aggressively marketed OxyContin starting in the 1990s via medical sales reps&nbsp;whose job was to convince doctors to prescribe more of their drug. Inappropriate prescribing of opioids was given as one of the major causes of U.S. overdoses, <a href="https://www.hhs.gov/opioids/statistics/index.html">according</a> to the office of Dept. of&nbsp;Health and Human Services.</p>
<p>"This story is about a family of cruel billionaires who believed they were above the law," said Connecticut Attorney General <strong>William Tong</strong> in a <a href="https://portal.ct.gov/ag/press-releases/2025-press-releases/purdue-pharma-and-sackler-family-settlement-in-principle">press release</a>. "Today, we're forcing Purdue and the Sackler family to pay for their role in one of the most devastating public health crises in American history."</p>
<p>Numerous U.S. states&nbsp;<a href="http://www.benzinga.com/markets/cannabis/21/07/21902857/15-states-settle-with-opioid-maker-purdue-pharma-for-4-5b-the-most-that-individuals-have-ever-pa">have sued Purdue Pharma</a>&nbsp;for its aggressive&nbsp;marketing and for downplaying OxyContin&#8217;s&nbsp;addictiveness. Purdue essentially responded by&nbsp;declaring bankruptcy in 2019.</p>
<p>Under the new terms, per Tong's press release, Purdue Pharma will cease to operate under Sackler control. Over the next 15 years, $7.4 billion will be distributed to communities across the U.S. for opioid addiction treatment, prevention and recovery initiatives. Notably, the Sackler family will no longer be shielded from future lawsuits, a demand they previously insisted upon in earlier agreements.</p>
<h2 class="wp-block-heading"><strong>Relentless Pursuit Of Profit</strong></h2>
<p>&#8220;Families throughout New York and across the nation are suffering from the immense pain and loss wrought by the opioid crisis,&#8221; said New York Attorney General <strong>Letitia James</strong>, whose office helped negotiate the settlement agreement, <a href="https://abcnews.go.com/Health/purdue-pharma-sackler-families-boost-contribution-opioid-settlement/story?id=118015777">reported</a> ABC News.</p>
<p>&#8220;The Sackler family relentlessly pursued profit at the expense of vulnerable patients, and played a critical role in starting and fueling in the opioid epidemic,&#8221; she continued. &#8220;While no amount of money will ever fully repair the damage they caused, this massive influx of funds will bring resources to communities in need so that we can heal.&#8221;</p>
<p>Purdue Pharma's earlier settlement plan included a <a href="https://www.benzinga.com/government/23/08/33748967/sackler-familys-6b-commitment-in-spotlight-supreme-court-suspends-purdue-pharmas-settlement-over-opi">$6 billion contribution from the Sacklers</a> in exchange for immunity from all civil opioid claims, even though the family itself did not file for bankruptcy. The Supreme Court struck down that arrangement, asserting that the Sacklers could not use the company's bankruptcy to shield themselves from liability.</p>
<p>A board of trustees will oversee Purdue&#8217;s future operations, ensuring it remains barred from opioid marketing or lobbying, noted Tong.</p>
<p>Purdue Pharma expressed satisfaction with the new settlement, in a statement to ABC News. The company said it will provide resources to combat the opioid epidemic and save lives.</p>
<p><strong>Now Read</strong>:</p>
<ul>
<li><a href="https://www.benzinga.com/24/12/42554729/pharmacy-benefit-managers-played-key-role-in-worsening-opioid-crisis-drug-makers-paid-staggering-rebates-to-the-middlemen"><strong>Pharmacy Benefit Managers Played Key Role in Worsening Opioid Crisis, Drug Makers Paid Staggering Rebates To Middlemen: NYT</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Cannabis

Politics

Legal

Purdue Pharma, Sackler Family To Pay $7.4 Billion In Settlement Over OxyContin That Fueled 'Devastating' Opioid Epidemic

<p>SB Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFG#NASDAQ">SBFG</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.41 by 26.83 percent. This is a 8.77 percent decrease over earnings of $0.57 per share from the same period last year.  The company reported quarterly sales of $15.454 million which beat the analyst consensus estimate of $9.900 million by 56.10 percent.  This is a 2.24 percent increase over sales of $15.115 million the same period last year.</p>


SB Finl Gr Q4 2024 Adj. EPS $0.52 Beats $0.41 Estimate, Sales $15.454M Beat $9.900M Estimate

<p>Virginia Ntl Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VABK#NASDAQ">VABK</a>) reported quarterly earnings of $0.85 per share. This is a 44.07 percent increase over earnings of $0.59 per share from the same period last year.</p>


VABK

Virginia Ntl Bankshares Q4 EPS $0.85 Up From $0.59 YoY

<p>Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 7.55 percent increase over earnings of $0.53 per share from the same period last year.</p>


Associated Banc Q4 EPS $0.57 Beats $0.53 Estimate

<p>OceanFirst Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCFC#NASDAQ">OCFC</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.36 by 5.56 percent. This is a 15.56 percent decrease over earnings of $0.45 per share from the same period last year.  The company reported quarterly sales of $83.329 million which missed the analyst consensus estimate of $85.152 million by 2.14 percent.  This is a 5.12 percent decrease over sales of $87.824 million the same period last year.</p>


Comments

Pear Therapeutics Inc Class A

Pear Therapeutics Inc Class A (PEARQ) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL